On Tuesday, Johnson & Johnson (NYSE:JNJ) agreed to acquire V-Wave for an upfront payment of $600 million, with the potential for additional regulatory and commercial milestone payments up to approximately $1.1 billion.

V-Wave is a privately held medical device company focused on developing heart failure and cardiovascular disease treatment options.

V-Wave will join Johnson & Johnson as part of Johnson & Johnson MedTech.

Also Read: Johnson & Johnson Nears Approval for $6.5B Long Standing Talc Settlement.

The planned acquisition of V-Wave will extend Johnson & Johnson MedTech’s position in addressing cardiovascular disease.

It will further accelerate its shift into high-growth and high-opportunity markets.

V-Wave’s Ventura ...